## **IN THE CLAIMS:**

- 1. (Withdrawn) Use of an endothelin blocker in combination with an  $\alpha_{\nu}\beta_{3}$  integrin receptor antagonist for the manufacture of medicaments for the treatment or prevention of diseases.
- 2. (Withdrawn) Use as claimed in claim 1 for the treatment or prevention of cardiovascular disorders.
- 3. (Withdrawn) Use as claimed in claim 2 for the treatment or prevention of restenosis after vessel injury or revascularisation treatment.
- 4. (Currently Amended) Pharmaceutical A pharmaceutical composition, for the treatment or prevention of cardiovascular diseases comprising an endothelin blocker and an α<sub>ν</sub>β<sub>3</sub> integrin receptor antagonist.

an endothelin blocker and an  $\alpha_V \beta_3$  integrin receptor antagonist.

- 5. (Cancel)
- 6. (Cancel)
- 7. (Withdrawn) Use of a composition as claimed in claim 4 for the manufacture of a medicament for the treatment or prevention of diseases.

- 8. (Withdrawn) Use as claimed in claim 7 for the treatment or prevention of cardiovascular disorders.
- 9. (Withdrawn) Use as claimed in claim 8 for the treatment or prevention of restenosis after vessel injury or revascularisation treatment.
- 10. (Currently Amended) Trade A trade package, comprising as pharmaceutical agent an endothelin blocker or/and an  $\alpha_v \beta_s$  integrin receptor antagonist together with an instruction for use of this pharmaceutical agents in combination for simultaneous, separate, or temporal graduated application for the treatment or prevention of diseases.

an endothelin blocker and an  $\alpha_V\beta_3$  integrin receptor antagonist as pharmaceutical agents and

instructions for use of these pharmaceutical agents in combination for simultaneous, separate or temporal graduated administration for the treatment or prevention of cardiovascular diseases.